| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051631258 |
| P356 | DOI | 10.1038/TPJ.2012.40 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/tpj.2012.40 |
| P698 | PubMed publication ID | 23044603 |
| P50 | author | Sam Harirforoosh | Q57018758 |
| P2093 | author name string | J E Wyatt | |
| W L Pettit | |||
| P2860 | cites work | Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? | Q42780908 |
| A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury | Q42966589 | ||
| CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin | Q43072828 | ||
| Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis | Q43506825 | ||
| In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics | Q43598159 | ||
| The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro | Q43877657 | ||
| Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles | Q43921957 | ||
| Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. | Q44085582 | ||
| Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes | Q44405606 | ||
| Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites | Q44534415 | ||
| CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians | Q44960515 | ||
| Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms | Q45004302 | ||
| Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method | Q45403032 | ||
| Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. | Q46257861 | ||
| Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. | Q48603971 | ||
| Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. | Q51769708 | ||
| The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. | Q54566435 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis | Q24646764 | ||
| Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase | Q24682914 | ||
| A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms | Q28203288 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial | Q28211411 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial | Q28211435 | ||
| UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin | Q28218275 | ||
| Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele | Q28373588 | ||
| Cyclooxygenase 2 and the kidney | Q31980676 | ||
| Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. | Q32072529 | ||
| Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development | Q33779438 | ||
| Aspirin as an antiplatelet drug | Q34338650 | ||
| Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis | Q34403797 | ||
| Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | Q34445132 | ||
| Clinical pharmacokinetics of ibuprofen. The first 30 years | Q34461383 | ||
| Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib | Q34531655 | ||
| Safety and efficacy of statins in Asians | Q34574500 | ||
| Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development | Q34985984 | ||
| Nonsteroidal anti-inflammatory drugs and heart failure | Q35091934 | ||
| Clinical consequences of cytochrome P450 2C9 polymorphisms | Q36002222 | ||
| Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? | Q36054094 | ||
| Pharmacogenetics of anesthetic and analgesic agents | Q36054508 | ||
| The pharmacogenetics of analgesia | Q36967259 | ||
| Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma | Q37219846 | ||
| Nonsteroidal anti-inflammatory drugs: effects on kidney function | Q37306896 | ||
| Renal adverse effects of nonsteroidal anti-inflammatory drugs | Q37615395 | ||
| Personalized therapy in pain management: where do we stand? | Q37760955 | ||
| Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. | Q41100709 | ||
| Broader Perspective Needed on the PharmD Degree in Pakistan | Q42597559 | ||
| Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans | Q42604782 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 462-467 | |
| P577 | publication date | 2012-10-09 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Pharmacogenetics of nonsteroidal anti-inflammatory drugs | |
| P478 | volume | 12 |
| Q49844896 | Anti-inflammatory profile of Aegle marmelos (L) Correa (Bilva) with special reference to young roots grown in different parts of India. |
| Q38991760 | IL-10 Gene Polymorphisms and Self-Medication With Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs |
| Q97551831 | Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective |
| Q36900075 | Pharmacogenetics of chronic pain and its treatment. |
| Q58139661 | Response |
| Q47213395 | The pharmacogenetics of medications used in general anesthesia |
| Q42792319 | The read-across hypothesis and environmental risk assessment of pharmaceuticals. |
Search more.